Articles producció científica> Enginyeria Electrònica, Elèctrica i Automàtica

Selection of an Aptamer against the Enzyme 1-deoxy-D-xylulose-5-phosphate Reductoisomerase from Plasmodium falciparum

  • Identification data

    Identifier: imarina:9287713
  • Authors:

    Roca, Carlota
    Avalos-Padilla, Yunuen
    Prieto-Simon, Beatriz
    Iglesias, Valentin
    Ramirez, Miriam
    Imperial, Santiago
    Fernandez-Busquets, Xavier
  • Others:

    Author, as appears in the article.: Roca, Carlota; Avalos-Padilla, Yunuen; Prieto-Simon, Beatriz; Iglesias, Valentin; Ramirez, Miriam; Imperial, Santiago; Fernandez-Busquets, Xavier;
    Department: Enginyeria Electrònica, Elèctrica i Automàtica
    URV's Author/s: Prieto Simón, Beatriz
    Keywords: Web server Protein-protein Plasmodium Pathway Methyl erythritol phosphate pathway Malaria Isoprenoid biosynthesis Inhibitors Evolution Drug targets Dna aptamers Apicoplast 1-deoxy-d-xylulose-5-phosphate reductoisomerase
    Abstract: The methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis is essential for malaria parasites and also for several human pathogenic bacteria, thus representing an interesting target for future antimalarials and antibiotics and for diagnostic strategies. We have developed a DNA aptamer (D10) against Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of this metabolic route. D10 binds in vitro to recombinant DXR from P. falciparum and Escherichia coli, showing at 10 mu M a ca. 50% inhibition of the bacterial enzyme. In silico docking analysis indicates that D10 associates with DXR in solvent-exposed regions outside the active center pocket. According to fluorescence confocal microscopy data, this aptamer specifically targets in P. falciparum in vitro cultures the apicoplast organelle where the MEP pathway is localized and is, therefore, a highly specific marker of red blood cells parasitized by Plasmodium vs. naive erythrocytes. D10 is also selective for the detection of MEP+ bacteria (e.g., E. coli and Pseudomonas aeruginosa) vs. those lacking DXR (e.g., Enterococcus faecalis). Based on these results, we discuss the potential of DNA aptamers in the development of ligands that can outcompete the performance of the well-established antibody technology for future therapeutic and diagnostic approaches.
    Thematic Areas: Pharmacology & pharmacy Pharmaceutical science Medicina ii Farmacia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: beatriz.prieto-simon@urv.cat
    Author identifier: 0000-0001-8016-1565
    Record's date: 2023-02-19
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/1999-4923/14/11/2515
    Papper original source: Pharmaceutics. 14 (11):
    APA: Roca, Carlota; Avalos-Padilla, Yunuen; Prieto-Simon, Beatriz; Iglesias, Valentin; Ramirez, Miriam; Imperial, Santiago; Fernandez-Busquets, Xavier; (2022). Selection of an Aptamer against the Enzyme 1-deoxy-D-xylulose-5-phosphate Reductoisomerase from Plasmodium falciparum. Pharmaceutics, 14(11), -. DOI: 10.3390/pharmaceutics14112515
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.3390/pharmaceutics14112515
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2022
    Publication Type: Journal Publications
  • Keywords:

    Pharmaceutical Science,Pharmacology & Pharmacy
    Web server
    Protein-protein
    Plasmodium
    Pathway
    Methyl erythritol phosphate pathway
    Malaria
    Isoprenoid biosynthesis
    Inhibitors
    Evolution
    Drug targets
    Dna aptamers
    Apicoplast
    1-deoxy-d-xylulose-5-phosphate reductoisomerase
    Pharmacology & pharmacy
    Pharmaceutical science
    Medicina ii
    Farmacia
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar